Diltiazem-cyclosporin pharmacokinetic interaction - dose-response relationship

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 499-504

  Jones, Terry E ^a   Morris, Raymond G ^a   Mathew, Timothy H ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Cyclosporin; Diltiazem; Dose response; Interaction; Metabolism; Pharmacokinetics; Transplantation

Indexed keywords

CYCLOSPORIN A; DILTIAZEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PERMISSIBLE DOSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030665572     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00616.x     Document Type: Article

References (36)

1. Barclay PG, Allen RDM, Stewart JH, Ng K, Chapman JR. Costs of immunosuppressive therapies used in renal transplantation. Transplant Proc 1992; 24: 165-166.
2. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, Pesce AJ. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 1989; ii: 1198-1201.
3. Powe NR, Eggers PW, Johnson CB. Early adoption of cyclosporine and recombinant human erythropoeitin: clinical, economic and polic issues with emergence of high cost drugs. Am J Kidney Dis 1994; 24: 33-41.
4. Editorial. Cyclosporin for ever? Lancet 1986; i: 419-420.
5. Patton PR, Brunson ME, Pfaff WW, et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporin-saparing effect and impact on transplant outcome. Transplantation 1994; 57: 889-892.
6. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991; 51: 365-370.
7. Kronbach T, Fischer V, Meyer UA. Cyclosporin metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporin-metabolizing enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
8. Combalbert J, Fahre I, Fabre G, et al. Purification and identification of the rifampicin-inducible liver cytochrome P-450 (cyclosporin A oxidase) as a product of the P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
9. Kolars JC, Awni WM, Merion RM, Watkins PB. First pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-1490.
10. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-497.
11. Slaughter RL, Edwards DJ. Recent advances: The cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619-624.
12. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin. Lancet 1986; i: 523.
13. Kohlhaw K, Wonigeit K, Frei U, Oldhafer K, Neumann K, Pichlmayr R. Effect of the calcium channel blocker diltiazem on cyclosporin A blood levels and dose requirements. Transplant Proc 1988; 20: Suppl 2: 572-574.
14. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporin after cardiac transplantation. N Engl J Med 1995; 333: 628-633.
15. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin. Lancet 1986; i: 523.
16. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporin. Transplantation 1993; 55: 300-304.
17. Valentine H, Keogh A, McIntosh N, Hunt S, Oyer P, Schroeder J. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. J Heart Lung Transplant 1992; 11: 1-8.
18. Sketris IS, Methot ME, Nicol D, Belitsky P, Knox MG. Effect of calcium-channel blockers on cyclosporin clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-1231.
19. Wagner K, Henkel M, Heinemeyer G, Neumayer HH. Interaction of calcium blockers and cyclosporine. Transplant Proc 1988; 20: Suppl 2: 561-568.
20. Brockmoller J, Neumayer HH, Wagner K, et al. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990; 38: 237-242.
21. Kohlaw K, Wonigeit K, Frei U, Oldhafer K, Neumann K, Pichlmayr R. Effect of the calcium channel blocker diltiazem on cyclosporin A blood levels and dose requirements, Transplant Proc 1988; 20, Suppl 2: 572-574.
22. Shennib H, Auger J. Diltiazem improves cyclosporin dosage in cystic fibrosis lung transplant recipients. J Heart Lung Transpl 1994; 13: 292-296.
23. Wagner K, Philipp Th, Heinenieyer G, Brockmuller F, Roots I, Neumayer HH. Interaction of cyclosporin and calcium antagonists. Transplant Proc 1989; 21: 1453-1456.
24. Henricsson S, Lindholm A. Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 1988; 20, Suppl 2: 569-571.
25. Jones TE. Survey of cyclosporin sparing agent use in Australasian transplant centres. Aust NZ J Med 1996; 26: 772-776.
26. Dusci LJ, Hackett P, Chiswell GM, Illett KF. Comparison of cyclosporin in whole blood by high performance liquid chromatography, monoclonal fluorescent polarization immunoassay and monoclonal enzyme multiplied immunoassay. Therap Drug Monit 1992; 14: 327-332.
27. Morris RG, Saccoia NC, Jones TE. Modified liquid chromatographic assay for diltiazem and metabolites in human plasma. J Liq Chrom Rel Technol 1996; 19: 2385-2394.
28. Morris RG, Jones TE, Mathew TH. Diltiazem disposition and metabolism in renal transplant recipients. Therap Drug Monit submitted for publication.
29. Jones TE, Morris RG. Survey of cyclosporin therapeutic ranges, assay methodology and use of sparing agents in Australasian transplant centres. Therap Drug Monit 1997; (in press).
30. Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci 1996; 85: 232-239.
31. Epstein M. Calcium antagonists and renal protection. Arch Int Med 1992; 152: 1573-1584.
32. Vasquez EM, Pollak R. Effect of calcium channel blockers on graft outcome in cyclosporine-treated renal allograft recipients. Transplantation 1995; 60: 885-887.
33. Wagner K, Albrecht S, Neumayer HH. Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem. A prospective randomised study. Am J Nephrol 1987; 7: 287-291.
34. Chen YL, Le Vraux V, Leneveu A, et al. Acute phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-660.
35. Jones TE, Morris RG, Mathew T. Formulation of diltiazem affects cyclosporin-sparing activity. Eur J Clin Pharmacol 1997; 52: 55-58.
36. Jones TE, Morris RG. Diltiazem does not always increase blood cyclosporin concentration. Br J Clin Pharmacol 1996; 42: 642-644.